Cwm LLC Grows Stock Holdings in Abbott Laboratories $ABT

Cwm LLC raised its position in Abbott Laboratories (NYSE:ABT) by 0.9% during the second quarter, Holdings Channel.com reports. The fund owned 265,467 shares of the healthcare product maker’s stock after purchasing an additional 2,252 shares during the quarter. Cwm LLC’s holdings in Abbott Laboratories were worth $36,106,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. Vanguard Personalized Indexing Management LLC increased its position in shares of Abbott Laboratories by 22.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 278,752 shares of the healthcare product maker’s stock valued at $37,936,000 after acquiring an additional 51,655 shares during the period. Hobbs Group Advisors LLC purchased a new position in shares of Abbott Laboratories during the second quarter valued at about $202,000. Sather Financial Group Inc increased its position in shares of Abbott Laboratories by 59.2% during the second quarter. Sather Financial Group Inc now owns 3,227 shares of the healthcare product maker’s stock valued at $439,000 after buying an additional 1,200 shares during the period. Concurrent Investment Advisors LLC increased its position in shares of Abbott Laboratories by 16.0% during the second quarter. Concurrent Investment Advisors LLC now owns 70,394 shares of the healthcare product maker’s stock valued at $9,574,000 after buying an additional 9,685 shares during the period. Finally, Cerro Pacific Wealth Advisors LLC increased its position in shares of Abbott Laboratories by 1.3% during the second quarter. Cerro Pacific Wealth Advisors LLC now owns 20,085 shares of the healthcare product maker’s stock valued at $2,732,000 after buying an additional 253 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Stock Performance

Shares of NYSE ABT opened at $132.30 on Friday. The stock has a market cap of $230.26 billion, a PE ratio of 16.58, a price-to-earnings-growth ratio of 2.51 and a beta of 0.69. The firm has a fifty day moving average price of $132.54 and a 200-day moving average price of $131.60. Abbott Laboratories has a 1 year low of $110.86 and a 1 year high of $141.23. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. The company had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. Abbott Laboratories’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period last year, the company posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be given a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is 29.57%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ABT shares. Leerink Partnrs upgraded shares of Abbott Laboratories to a “hold” rating in a research report on Monday, June 16th. The Goldman Sachs Group upped their target price on shares of Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a research note on Wednesday, October 1st. Mizuho upped their target price on shares of Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 16th. Weiss Ratings restated a “buy (b)” rating on shares of Abbott Laboratories in a research report on Wednesday. Finally, BTIG Research reduced their target price on shares of Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a report on Friday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $146.17.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.